SLC2A1 and cancer: We used cancer cell lines, nude mice with A549 tumors or GLUT1-deficient A549 tumors, and metabolomics analysis was used to identify our compound’s anticancer efficacy and mechanisms in vitro and in vivo as a pan-class I GLUT inhibitor.